Status:
WITHDRAWN
Novel Triple-dose Tuberculosis Retreatment Regimens: How to Overcome Resistance Without Creating More
Lead Sponsor:
Institute of Tropical Medicine, Belgium
Collaborating Sponsors:
Damien Foundation
Conditions:
Tuberculosis, Pulmonary
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
Drug-resistance is a major challenge for tuberculosis (TB) care programs. The new WHO guideline recommends adding levofloxacin in previously treated patients with isoniazid-resistant rifampicin-suscep...
Eligibility Criteria
Inclusion
- All newly registered patients with smear-positive recurrent pulmonary TB
- Adults as well as children (no age limit)
- Able and willing to provide written informed consent
Exclusion
- Patients transferred to a health facility not supported by Damien Foundation will be excluded. This includes patients diagnosed with HIV/TB-coinfection.
Key Trial Info
Start Date :
September 30 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03862248
Start Date
September 30 2019
End Date
October 1 2022
Last Update
January 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien Foundation
Dhaka, Bangladesh